Stock Market & Financial Investment News

News Breaks March 11, 2013 08:08 EDT CSII Cardiovascular Systems presents results from ORBIT II study ORBIT II is evaluating the safety and effectiveness of the company's orbital atherectomy technology in treating a problematic subset of patients with severely calcified coronary lesions and is the first Investigational Device Exemption study in history to seek approval for treating these lesions.Dr. Jeffrey Chambers said, "While treatment of severely calcified coronary arteries remains a challenge, 30-day ORBIT II results show that study endpoints were met by a significant margin, and demonstrate that CSI's orbital atherectomy system may be a viable treatment option. ORBIT II represents the only study to-date of this hard-to-treat patient population. Past studies haven't attempted to treat severely calcified lesions, due to the challenge of meeting endpoints and overall treatment success." News For CSII From The Last 14 Days Check below for free stories on CSII the last two weeks. Sign up for a free trial to see the rest of the stories you've been missing. June 6, 2013 10:12 EDT CSII Cardiovascular Systems reports new data from CONFIRM study series Subscribe for More Information Sign up for a free trial to see the rest of the stories you've been missing.